Loading clinical trials...
Loading clinical trials...
Comparison of the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune) Plasma Among Outpatients With Symptomatic COVID-19
Conditions
Interventions
SARS-CoV-2 convalescent plasma
Plasma from a volunteer donor
Locations
29
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Center for American Indian Health - Chinle Office
Chinle, Arizona, United States
Mayo Clinic, Phoenix
Phoenix, Arizona, United States
University of Arizona, Phoenix
Tucson, Arizona, United States
University of Arizona, Tuscon
Tucson, Arizona, United States
Center for American Indian Health - Whiteriver Office
Whiteriver, Arizona, United States
Start Date
June 3, 2020
Primary Completion Date
January 14, 2022
Completion Date
December 14, 2022
Last Updated
June 2, 2023
NCT04568148
NCT04405362
NCT04797091
NCT04405271
NCT04448717
NCT04378686
Lead Sponsor
Johns Hopkins University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions